セフォラニド

危険有害性情報のコード(GHS)

• 絵表示(GHS)

  

• 注意喚起語

  Danger

• 危険有害性情報

  H317：アレルギー性皮膚反応を起こすおそれ

  H334：吸入するとアレルギー、喘息または、呼吸困難 を起こすおそれ

• 注意書き

  P261：粉じん/煙/ガス/ミスト/蒸気/スプレーの吸入を避ける こと。

  P280：保護手袋/保護衣/保護眼鏡/保護面を着用するこ と。

  P284：呼吸用保護具を着用すること。

  P304+P340：吸入した場合：空気の新鮮な場所に移し、呼吸しやすい 姿勢で休息させること。

  P342+P311：呼吸に関する症状が出た場合：医師に連絡すること。

セフォラニド 価格

セフォラニド 化学特性,用途語,生産方法

• 効能

  抗生物質, 細胞壁合成阻害薬

• 説明

  Ceforanide is a second generation cephalosporin with good β-lactamase resistance. It has a serum half-life of about three hours, allowing twice-daily dosing.

• 使用

  Ceforanide is a cephalosporin based antibiotic used in the sterilization in various medical procedures.

• 定義

  ChEBI: A second-generation cephalosporin antibiotic with {[1-(carboxymethyl)-1H-tetrazol-5-yl]sulfanyl}methyl and 2-(aminomethyl)phenylacetamido groups at positions 3 and 7, respectively, of the cephem skeleton. It is effective against many col forms, including Escherichia coli, Klebsiella, Enterobacter and Proteus, and most strains of Salmonella, Shigella, Hemophilus, Citrobacter and Ari ona species.

• 抗菌性

  A semisynthetic parenteral cephalosporin with activity broadly similar to that of cefalotin. Its activity in vitro is significantly reduced in the presence of serum. A 1 g intravenous dose achieves a concentration of c. 135 mg/L at the end of infusion. The response after 0.25, 0.5 and 1 g intravenous doses is essentially linear. A 1 g intramuscular dose produces mean peak values of around 70 mg/L. Plasma protein binding is around 85%.
  It is almost entirely eliminated in the urine with a halflife of about 2.5 h, 80–95% being recovered in the first 12 h. The half-life is inversely related to renal function, rising to around 20 h when the creatinine clearance falls below 5 mL/min. About half the dose is removed by hemodialysis over 6 h.
  It is generally well tolerated; phlebitis and pain at the site of injection are reported in some patients with occasional transient neutropenia and increased transaminase levels. It has been used principally for the treatment of infections due to Gram-positive cocci, including staphylococcal and streptococcal soft-tissue infections, but is no longer widely available.

セフォラニド 生産企業

Global(87)Suppliers

60925-61-3, セフォラニド キーワード